Ironwood Q2 2022 GAAP net income $37M; LINZESS Rx demand up 9% YoY; guidance reiterated

IRONWOOD PHARMACEUTICALS INC

2022-Q1 EPS reported $0.42 revenue$194,760,000

GAAP net income of $37M ($0.21 diluted EPS); adjusted EBITDA of $56M; total revenue $97.2M, down 7% YoY.
LINZESS EUTRx prescription demand grew 9% year-over-year in Q2 2022.
Completed $75M share repurchase program and repaid remaining 2022 Convertible Notes in cash.
Reiterated 2022 guidance: low single-digit % LINZESS net sales growth, total revenue $420-$430M, adjusted EBITDA >$250M.
Phase 3 pediatric linaclotide study for functional constipation expected to readout in Q3 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.